Alivus Life Sciences Dividends and Buybacks
Dividend criteria checks 2/6
Alivus Life Sciences is a dividend paying company with a current yield of 2.21%.
Key information
2.2%
Dividend yield
-0.0008%
Buyback Yield
| Total Shareholder Yield | 2.2% |
| Future Dividend Yield | 2.5% |
| Dividend Growth | -23.0% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹22.500 |
| Payout ratio | 0% |
Recent dividend and buyback updates
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, GLS has been paying a dividend for less than 10 years.
Growing Dividend: GLS's dividend payments have increased, but the company has only paid a dividend for 3 years.
Dividend Yield vs Market
| Alivus Life Sciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GLS) | 2.2% |
| Market Bottom 25% (IN) | 0.2% |
| Market Top 25% (IN) | 1.1% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (GLS) (up to 3 years) | 2.5% |
Notable Dividend: GLS's dividend (2.21%) is higher than the bottom 25% of dividend payers in the Indian market (0.24%).
High Dividend: GLS's dividend (2.21%) is in the top 25% of dividend payers in the Indian market (1.08%)
Earnings Payout to Shareholders
Earnings Coverage: Unable to calculate sustainability of dividends as GLS has not reported any payouts.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (104%), GLS's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:52 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alivus Life Sciences Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saad Shaikh | BOB Capital Markets Ltd. |
| Neha Manpuria | BofA Global Research |
| Nitin Agarwal | DAM Capital Advisors |